{"name":"Immutep S.A.S.","slug":"immutep-s-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"cisplatin or carboplatin + pemetrexed","genericName":"cisplatin or carboplatin + pemetrexed","slug":"cisplatin-or-carboplatin-pemetrexed","indication":"Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy)","status":"phase_3"}]}],"pipeline":[{"name":"cisplatin or carboplatin + pemetrexed","genericName":"cisplatin or carboplatin + pemetrexed","slug":"cisplatin-or-carboplatin-pemetrexed","phase":"phase_3","mechanism":"This combination uses platinum-based chemotherapy (cisplatin or carboplatin) plus pemetrexed, a folate antagonist that inhibits multiple enzymes in nucleotide synthesis, to damage cancer cell DNA and disrupt cell division.","indications":["Non-small cell lung cancer (likely in combination with immunotherapy, given Immutep's focus on LAG-3 immunotherapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"trial","source":"Medical Dialogues","summary":"Dr Reddy's Partner Immutep Halts Phase III Trial of Eftilagimod Alfa in Lung Cancer Study - Medical Dialogues","headline":"Dr Reddy's Partner Immutep Halts Phase III Trial of Eftilagimod Alfa in Lung Cancer Study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQUkVaNUtzTzZPU0RDZlN6dFJXWnF0QVhzTmpQNWJ1bGtNUUt4WEthWHdBUm1kcUJQVklDWTlNSGF3QzVPbFpXYzJ6enF0cTJDRTBwVVA2SkxpcVFDVXVoNFNJbFloNHJPQ0daekF5TFdiRG1RVHdiOElzTzJiRmU4bFhZWGJLQURfMjNDVVpDMkc2X0IxQWwtSWg2RUI2M3FtWUV6Qmo0dU5tZnBVZUhCYXZTN3M0aXgwR2JlS2x6VGx6WkdkVmhsQTcxNmRPVzBLOHlR?oc=5","date":"2025-12-08","type":"deal","source":"BioSpectrum Asia","summary":"Australia's Immutep inks oncology deal worth $349.5 M with Indian pharma firm Dr. Reddy's - BioSpectrum Asia","headline":"Australia's Immutep inks oncology deal worth $349.5 M with Indian pharma firm Dr. Reddy's","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-08","type":"pipeline","source":"Business Standard","summary":"Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug - Business Standard","headline":"Dr Reddy's signs licensing pact with Immutep to develop, market cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOWVFsZHdSbjYxcjJocHNIUHlIbHp4WEthc0dDT2RLNVBTMkdJbmwxckJQR2g3Rm9VbmpkM0UyYmttZDVQR25jWDA4blFlVmZzbWl1OWFkeWpzR0pwZFJYQmRBa1lLYWNhaFpVdWRXUkVrZEtQd29Tc2tTc0c4YWxJNzEwaDZJR2pkZTgtSEptV2g1MFYwUkd2bnp0Q1lCZDFzc1oxbFp1TDR2V1E50gGyAUFVX3lxTE5lYjl1ZUlMdkxZcV9UZHR1a2JOMFEtS3RUZHJ6TFhvcWMtRkRxVnB6VEhES21peWtVcFZPSkRqU1hUM1RvcFlMRmpGZnJvNXRlQnFkUnJyelBIWmxTektTS2VYbU9pek4tWkNXbDJpbVlXMHBpcVVtU1lldlRweTRNX3E0TjhUV19HbVV6Q21TZUx1cnJ5UDFMSFpPd2M2ZjdUOE91QlFURlNBOF8wOTdnYWc?oc=5","date":"2025-12-08","type":"pipeline","source":"Express Pharma","summary":"Immutep and Dr Reddy’s enter Exclusive Licensing Agreement for Eftilagimod Alfa - Express Pharma","headline":"Immutep and Dr Reddy’s enter Exclusive Licensing Agreement for Eftilagimod Alfa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOdTJ5TWJxeDVSbHdsenRhNzBTQmZEVHFpUHBUWmVvSGVNelQ1dWVuR0JkVDBOUGg1MTg0QVVKalZES2NuQTBwaENWZEFCMDlZSWF2MEhXTFlwUl9DNE9rYnM5SU5RTjlqaTBjRnlaQ29lLUM4SDhuazZPMTFONmtnUUItWGRVS3p3eEZSMWhwSVBvam9naFdOTXZLOUY4c0R0UTdz0gGoAUFVX3lxTE1ldWJJek1OcWs5V0dCc0hEMXg2YmxRakd3aFBzMElFSDJrN3d2ZUtfdFU1b1Nmc3NzLWRnQXJ0WDNKSmN1TWxxYWR5d1ZMYXZpcWRPLXhPb3hPaVBPc09ZLU45VkRRRXA2SG1vSFVCbHk3Skl1WWdRVG9VV1MwS3dKMTZ6NDlBMF9icmhSOWNVc2RhSFViMGZwU1RDQ3NMN0s0bjlYdlZnTA?oc=5","date":"2025-12-08","type":"pipeline","source":"Rediff MoneyWiz","summary":"Dr Reddy''s & Immutep Ink Cancer Drug Licensing Pact - Rediff MoneyWiz","headline":"Dr Reddy''s & Immutep Ink Cancer Drug Licensing Pact","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-08","type":"deal","source":"CNBC TV18","summary":"Dr Reddy’s arm signs exclusive licensing deal with Immutep for novel cancer therapy - CNBC TV18","headline":"Dr Reddy’s arm signs exclusive licensing deal with Immutep for novel cancer therapy - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-08","type":"pipeline","source":"Business Standard","summary":"Dr Reddy's Lab arm inks pact with Immutep SAS for novel cancer immunotherapy - Business Standard","headline":"Dr Reddy's Lab arm inks pact with Immutep SAS for novel cancer immunotherapy","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}